Lenalidomide efficacy in activated B-cell-like subtype diffuse large B-cell lymphoma is dependent upon IRF4 and cereblon expression

Exploiting Synthetic Lethality for the Therapy of ABC Diffuse Large B Cell Lymphoma

(2012) Yibin Yang et al.   CANCER CELL

An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma

(2011) T. E. Witzig et al.   ANNALS OF ONCOLOGY

A review of the history, properties, and use of the immunomodulatory compound lenalidomide

(2011) Jerome B. Zeldis et al.   Annals of the New York Academy of Sciences

IMiD immunomodulatory compounds block C/EBP  translation through eIF4E down-regulation resulting in inhibition of MM

(2011) S. Li et al.   BLOOD

Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide

(2011) Y. X. Zhu et al.   BLOOD

The differential effect of lenalidomide monotherapy in patients with relapsed or refractory transformed non-Hodgkin lymphoma of distinct histological origin

(2011) Myron S. Czuczman et al.   BRITISH JOURNAL OF HAEMATOLOGY

Lenalidomide downregulates the cell survival factor, interferon regulatory factor-4, providing a potential mechanistic link for predicting response

(2011) Antonia Lopez-Girona et al.   BRITISH JOURNAL OF HAEMATOLOGY

Higher response to lenalidomide in relapsed/refractory diffuse large B-cell lymphoma in nongerminal center B-cell-like than in germinal center B-cell-like phenotype

(2011) Francisco J. Hernandez-Ilizaliturri et al.   CANCER

Protein Kinase C Inhibitor Sotrastaurin Selectively Inhibits the Growth of CD79 Mutant Diffuse Large B-Cell Lymphomas

(2011) T. L. Naylor et al.   CANCER RESEARCH

Lenalidomide can be safely combined with R-CHOP (R2CHOP) in the initial chemotherapy for aggressive B-cell lymphomas: phase I study

(2011) G S Nowakowski et al.   LEUKEMIA

Activation of the p53 pathway by the MDM2 inhibitor nutlin-3a overcomes BCL2 overexpression in a preclinical model of diffuse large B-cell lymphoma associated with t(14;18)(q32;q21)

(2011) E Drakos et al.   LEUKEMIA

Novel therapeutic agents for B-cell lymphoma: developing rational combinations

(2010) C. B. Reeder et al.   BLOOD

MLN4924, a NEDD8-activating enzyme inhibitor, is active in diffuse large B-cell lymphoma models: rationale for treatment of NF- B-dependent lymphoma

(2010) M. A. Milhollen et al.   BLOOD

The pan-HDAC inhibitor vorinostat potentiates the activity of the proteasome inhibitor carfilzomib in human DLBCL cells in vitro and in vivo

(2010) G. Dasmahapatra et al.   BLOOD

CAL-101, a p110  selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability

(2010) B. J. Lannutti et al.   BLOOD

Immunohistochemical Methods for Predicting Cell of Origin and Survival in Patients With Diffuse Large B-Cell Lymphoma Treated With Rituximab

(2010) Paul N. Meyer et al.   JOURNAL OF CLINICAL ONCOLOGY

Novel disease targets and management approaches for diffuse large B-cell lymphoma

(2010) Wyndham H. Wilson et al.   LEUKEMIA & LYMPHOMA

Oncogenically active MYD88 mutations in human lymphoma

(2010) Vu N. Ngo et al.   NATURE

Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma

(2010) R. Eric Davis et al.   NATURE

Critical role of PI3K signaling for NF- B-dependent survival in a subset of activated B-cell-like diffuse large B-cell lymphoma cells

(2010) B. Kloo et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Identification of a Primary Target of Thalidomide Teratogenicity

(2010) T. Ito et al.   SCIENCE

Oncogenic Activation of NF- B

(2010) L. M. Staudt   Cold Spring Harbor Perspectives in Biology

Antigen Receptor Signaling to NF- B via CARMA1, BCL10, and MALT1

(2010) M. Thome et al.   Cold Spring Harbor Perspectives in Biology

Follicular lymphoma cells induce T-cell immunologic synapse dysfunction that can be repaired with lenalidomide: implications for the tumor microenvironment and immunotherapy

(2009) A. G. Ramsay et al.   BLOOD

Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma

(2009) K. Dunleavy et al.   BLOOD

Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia

(2009) J. W. Friedberg et al.   BLOOD

Masking MALT1: the paracaspase's potential for cancer therapy

(2009) Domagoj Vucic et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Inhibition of MALT1 protease activity is selectively toxic for activated B cell–like diffuse large B cell lymphoma cells

(2009) Uta Ferch et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Mechanism of action of lenalidomide in hematological malignancies

(2009) Venumadhav Kotla et al.   Journal of Hematology & Oncology

Essential role of MALT1 protease activity in activated B cell-like diffuse large B-cell lymphoma

(2009) S. Hailfinger et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Lenalidomide Monotherapy in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma

(2008) Peter H. Wiernik et al.   JOURNAL OF CLINICAL ONCOLOGY

IRF4 addiction in multiple myeloma

(2008) Arthur L. Shaffer et al.   NATURE

Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways

(2008) G. Lenz et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Oncogenic CARD11 Mutations in Human Diffuse Large B Cell Lymphoma

(2008) G. Lenz et al.   SCIENCE

Targeted Treatment and New Agents in Diffuse Large B-Cell Lymphoma

(2008) John P. Leonard et al.   SEMINARS IN HEMATOLOGY